The Europe Periodontal Disease Treatment Market was valued at $942.2 Million in 2024 and projected to reach to $1239.4 Million by 2029, representing a compound annual growth rate of 4.7%. Europe's periodontal disease treatment market is positioned for steady expansion through 2029, driven by an aging population with increasing oral health awareness and rising prevalence of periodontal conditions.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Europe's periodontal disease treatment market valued at $942.2 million in 2024, expanding at 4.7% CAGR through 2029, reflecting a mature healthcare landscape with consistent demand for advanced periodontal solutions.
Europe's aging demographic significantly increases periodontal disease prevalence, creating sustained demand for preventive and therapeutic treatment options across dental practices and specialized clinics.
European healthcare systems demonstrate strong adoption of cutting-edge periodontal technologies including laser therapy, regenerative procedures, and digital diagnostics, supporting market expansion.
Key European markets including UK ($124.38M), Italy ($196.42M), and Spain ($153.67M) lead regional growth, supported by robust healthcare infrastructure and high treatment accessibility standards.
| Report Metric | Details |
|---|---|
| Base Year | 2024 |
| Fastest Growing Segment | AGGRESSIVE PERIODONTITIS (Disease) |
| Forecast Period | 2024–2029 |
| Growth Rate | CAGR of 5.9% from 2024 to 2029 |
| Largest Segment | NON-SURGICAL TREATMENT (Treatment) |
| Market Size Base Year (Billions) | ~USD 2.57 (2024) |
| Revenue Forecast (Billions) | ~USD 3.43 (2029) |
| Segments Covered | Product, Disease, Type, Treatment |
4 segment dimensions are covered across the global market.
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| DENTSPLY SIRONA | United States | Public Company | Connected Technology Solutions,Essential Dental Solutions,Orthodontic and Implant Solutions, |
| ENVISTA HOLDINGS CORPORATION | United States | Public Company | Specialty Products & Technologies – Implants & Biomaterials,Specialty Products & Technologies – Orthodontics & Clear Aligners,Equipment & Consumables – Imaging, Software & Visualization, |
| HENRY SCHEIN, INC. | United States | Public Company | Global Distribution and Value-Added Services,Global Specialty Products,Global Technology, |
| BIOLASE, INC. | United States | Public Company | Waterlase all-tissue systems,Diode soft-tissue systems,Consumables, fibers, and handpieces, |
| NAKANISHI INC. | Japan | Public Company | Dental handpieces (air turbines, contra-angles, micromotors),Surgical and mobile dentistry systems,Dental lab, hygiene, and maintenance products, |
| A-DEC INC. | Switzerland | Public Company | Flexible placement (temporary staffing and contracting),Permanent placement and career transition,Outsourcing and engineering consulting, |
DENTSPLY SIRONA is a United States-based public company founded in 1877 with 14,000 employees. The company operates in the dental industry.
ENVISTA HOLDINGS CORPORATION is a United States-based public company founded in 2018 with 12,000 employees. The company operates in the dental industry.
HENRY SCHEIN, INC. is a United States-based public company founded in 1932 with 25,000 employees. The company operates in the dental industry.
BIOLASE, INC. is a United States-based public company founded in 1984 with 157 employees. The company operates in the dental industry.
NAKANISHI INC. is a Japan-based public company founded in 1930 with 2,204 employees. The company operates in the dental industry.
A-DEC INC. is a Switzerland-based public company founded in 1957 with 33,569 employees. The company operates in the dental industry.
| Country | 2025 size (native) |
|---|---|
| Germany | USD 87.86 Million |
| France | USD 54.73 Million |
| UK | USD 124.38 Million |
| Italy | USD 196.42 Million |
| Spain | USD 153.67 Million |
| Rest Of Europe | USD 54.15 Million |
Europe's periodontal disease treatment market was valued at $942.2 million in 2024 and is expected to grow to $1,239.4 million by 2029.
Europe's periodontal disease treatment market is projected to grow at a compound annual growth rate (CAGR) of 4.7% from 2024 to 2029.
Key drivers include Europe's aging population, rising prevalence of periodontal disease, increased healthcare spending, widespread dental insurance coverage, and growing adoption of advanced treatment technologies such as laser therapy and regenerative procedures.
Europe is seeing increased adoption of minimally invasive procedures, digital dentistry solutions, laser-based therapies, bone grafting, implant-based treatments, and regenerative periodontal therapies.
Europe's 4.7% CAGR is slightly lower than the global 5.9% CAGR, reflecting Europe's mature market status; however, Europe maintains higher per-capita spending and more advanced treatment adoption rates than many other regions.
Full forecast, segment splits, and company analysis for all Periodontal Disease Treatment Market.
Customize this report to your needs
Get 10% FREE Customization
Customize This Report